Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

11/14/24 6:57:50 PM ET

$ALGS

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ALGS alert in real time by email

SC 13G/A 1 ea022116102-13ga1viv8_aligos.htm AMENDMENT NO. 1 TO SCHEDULE 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Aligos Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

01626L204

(CUSIP Number)

September 30, 2024

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐

Rule 13d-1(b)

☒

Rule 13d-1(c)

☐

Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 01626L204
1	NAMES OF REPORTING PERSONS
	Vivo Capital Fund VIII, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
	(a) ☐
	(b) ☒
3	SEC USE ONLY

4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER
			124,665 ⁽¹⁾
		6	SHARED VOTING POWER
			0
		7	SOLE DISPOSITIVE POWER
			124,665 ⁽¹⁾
		8	SHARED DISPOSITIVE POWER
			0
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	124,665 ⁽¹⁾
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	3.5% ⁽²⁾
12	TYPE OF REPORTING PERSON (See Instructions)
	PN

⁽¹⁾

The shares of common stock, $0.0001 par value (“Common Stock”) of Aligos Therapeutics, Inc. (the “Issuer”) are held of records by Vivo Capital Fund VIII, L.P. as of October 31, 2024. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P.

⁽²⁾

Based on 3,587,892 shares of Common Stock outstanding as of November 4, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the “SEC”) on November 6, 2024.

CUSIP No. 01626L204
1	NAMES OF REPORTING PERSONS
	Vivo Capital Surplus Fund VIII, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
	(a) ☐
	(b) ☒
3	SEC USE ONLY

4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER
			17,214 ⁽¹⁾
		6	SHARED VOTING POWER
			0
		7	SOLE DISPOSITIVE POWER
			17,214 ⁽¹⁾
		8	SHARED DISPOSITIVE POWER
			0
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	17,214 ⁽¹⁾
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	0.5% ⁽²⁾
12	TYPE OF REPORTING PERSON (See Instructions)
	PN

(1)

The shares of Common Stock of the Issuer are held of records by Vivo Capital Surplus Fund VIII, L.P. as of October 31, 2024. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P.

(2)

Based on 3,587,892 shares of Common Stock outstanding as of November 4, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on November 6, 2024.

CUSIP No. 01626L204
1	NAMES OF REPORTING PERSONS
	Vivo Capital VIII, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
	(a) ☐
	(b) ☒
3	SEC USE ONLY

4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER
			141,879 ⁽¹⁾
		6	SHARED VOTING POWER
			0
		7	SOLE DISPOSITIVE POWER
			141,879 ⁽¹⁾
		8	SHARED DISPOSITIVE POWER
			0
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	141,879 ⁽¹⁾
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	4.0% ⁽²⁾
12	TYPE OF REPORTING PERSON (See Instructions)
	OO

(1)

The shares of Common Stock of the Issuer are held of records by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. as of October 31, 2024. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P.

(2)

Based on 3,587,892 shares of Common Stock outstanding as of November 4, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on November 6, 2024.

Item 1. (a)

Name of Issuer:

Aligos Therapeutics, Inc.

(b)

Address of Issuer’s Principal Executive Offices:

One Corporate Dr., 2nd Floor

South San Francisco, California 94080

Item 2. (a)

Name of Person Filing:

Vivo Capital Fund VIII, L.P.

Vivo Capital Surplus Fund VIII, L.P.

Vivo Capital VIII, LLC

(b)

Address of Principal Business Office or, if None, Residence:

192 Lytton Avenue, Palo Alto, CA 94301

(c)

Citizenship:

Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. are Delaware limited partnerships.

Vivo Capital VIII, LLC is a Delaware limited liability company

(d)

Title of Class of Securities:

Common stock, $0.0001 par value

(e)

CUSIP Number:

01626L204

Item 3.

If This Statement is Filed Pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

(a)	☐	Broker or dealer registered under Section 15 of the Act.

(b)	☐	Bank as defined in Section 3(a)(6) of the Act.

(c)	☐	Insurance company as defined in Section 3(a)(19) of the Act.

(d)	☐	Investment company registered under Section 8 of the Investment Company Act of 1940.

(e)	☐	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)	☐	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)	☐	A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);

(h)	☐	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

(i)	☐	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

(j)	☐	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

(k)	☐	Group, in accordance with § 240.13d-1(b)(l)(ii)(K).

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution: ________________

Not Applicable.

Item 4.

Ownership.

(a)

Amount beneficially owned:

The securities are held of records by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of both Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P.

(b)

Percent of class: 4.0%

(c)

Number of shares as to which such person has:

(i)

Sole power to vote or to direct the vote:

Vivo Capital Fund VIII, L.P.: 124,665 shares

Vivo Capital Surplus Fund VIII, L.P.: 17,214 shares

Vivo Capital VIII, L.P.: 141,879 shares

(ii)

Shared power to vote or to direct the vote: 0

(iii)

Sole power to dispose or to direct the disposition of:

Vivo Capital Fund VIII, L.P.: 124,665 shares

Vivo Capital Surplus Fund VIII, L.P.: 17,214 shares

Vivo Capital VIII, L.P.: 141,879 shares

(iv)

Shared power to dispose of or to direct the disposition of: 0

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable.

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	Vivo Capital Fund VIII, L.P.

	By: Vivo Capital VIII, LLC, its General Partner

	November 14, 2024
	(Date)

	/s/ Frank Kung
	(Signature)

	Managing Member
	(Title)

	Vivo Capital Surplus Fund VIII, L.P.

	By: Vivo Capital VIII, LLC, its General Partner

	November 14, 2024
	(Date)

	/s/ Frank Kung
	(Signature)

	Managing Member
	(Title)

	Vivo Capital VIII, LLC

	November 14, 2024
	(Date)

	/s/ Frank Kung
	(Signature)

	Managing Member
	(Title)

EXHIBIT INDEX

Exhibit
99.1		Joint Filing Statement

Get the next $ALGS alert in real time by email

Date	Price Target	Rating	Analyst
8/19/2024	$75.00	Buy	H.C. Wainwright
1/6/2023	$2.00 → $3.00	Neutral → Overweight	Piper Sandler
1/6/2023	$2.50 → $3.00	Hold → Buy	Jefferies
3/23/2022	$15.00 → $4.00	Overweight → Neutral	Piper Sandler
3/11/2022	$47.00 → $15.00	Overweight	Piper Sandler
3/11/2022	$10.00 → $11.00	Outperform	SVB Leerink
2/16/2022	$15.00 → $10.00	Outperform	SVB Leerink
1/7/2022	$30.00 → $12.00	Overweight → Neutral	JP Morgan

Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for $ALGS

$ALGS SEC Filings

SEC Form EFFECT filed by Aligos Therapeutics Inc.

SEC Form S-8 filed by Aligos Therapeutics Inc.

SEC Form S-3 filed by Aligos Therapeutics Inc.

$ALGS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Chief Medical Officer Achneck Hardean

SEC Form 3 filed by new insider Achneck Hardean

SEC Form 4 filed by Calhoun Lesley Ann

$ALGS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on Aligos Therapeutics with a new price target

Aligos Therapeutics upgraded by Piper Sandler with a new price target

Aligos Therapeutics upgraded by Jefferies with a new price target

$ALGS Market Insights

Live Market Insights

Aligos Therapeutics And Amoytop To Sponsor Phase 1b Study Evaluating Efficacy And Safety Of ALG-000184 With PEGBING In CHB Patients

Aligos Therapeutics To Host Key Opinion Leader Event To Discuss The Phase 1b Data From ALG-000184 For The Treatment Of CHB

Aligos Therapeutics Presented Poster Highlighting The Continued Potent Antiviral Activity Of ALG-000184 For Chronic Hepatitis B (CHB) In Both Hbeag-Positive And Hbeag-Negative Subjects At The EASL Congress 2024

$ALGS Large Ownership Changes

This live feed shows all institutional transactions in real time.